Arginine Hydrochloride, Lysine Hydrochloride

4 trials 3 recruiting VVarious

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

3 Recruiting

1 Completed trials

3 Sponsors

10 Countries

Phase III

Phase II

Phase I/II

Phase I (Other)

Phase III: 1 Phase II: 1 Phase I/II: 1 Phase I (Other): 1

Oversight events:

1 unexpected event across 1 trial

View oversight register →

Indications tested

Gastroenteropancreatic neuroendocrine tumour disease 1 Small cell lung cancer extensive stage 1

Sponsors using this IMP

Novartis Pharma AG 2 Centre Hospitalier Universitaire De Bordeaux 1 Oncopole Claudius Regaud 1

All trials

4 total

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab. Recruiting

2024-513185-19-00 Phase I/II 8 countries Novartis Pharma AG
Study to evaluate the efficacy and safety of [177Lu]Lu-DOTA-TATE in patients with Grade 1 and Grade 2 advanced GEP-NET (NETTER-3) Recruiting

2024-518325-15-00 Phase III 7 countries Novartis Pharma AG
Intra-arterial hepatic (IAH) infusion of radiolabelled somatostatin analogs in GEP-NET patients with dominant liver metastases Recruiting

2024-514785-39-00 Phase II 1 country Centre Hospitalier Universitaire De Bordeaux
A Phase I Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTA0-Tyr3-Octreotate in Children … Ended

2024-515552-21-00 Phase I (Other) 1 country Oncopole Claudius Regaud

Showing 1–4 of 4 trials

← All drugs A–Z